In this episode of The Oncology Insights Podcast, I speak with Dr. Tony Abraham, President and Medical Director, and Daniel Varghese, CEO of RadiantPath Health, about expanding access to nuclear theranostics in oncology. They explore mobile delivery of Lu-177 PSMA therapy, regulatory and staffing barriers, and patient-centered care models, and examine how bringing advanced treatments into community settings can reduce travel burden and improve therapy completion. Daniel and Dr. Abraham also highlight the role of artificial intelligence, safety standards, and future applications beyond prostate cancer. Listen now on all major platforms!

"Theranostics allows clinicians to precisely identify cancer targets through imaging and then deliver treatment directly to those same sites, minimizing damage to surrounding healthy tissues." - Dr. Tony Abraham

Meet the guests:

Daniel Varghese is a board-certified Physician Assistant and CEO of RadiantPath Health, leading the first mobile nuclear medicine unit in the United States.

Dr. Tony Abraham is a Nuclear Medicine Physician with fellowship training in PET/CT and nuclear oncology, and over 20 years of experience advancing targeted therapeutics in cancer care.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:42) Introduction
• (07:28) Theranostics explained
• (10:11) Patient experience
• (12:10) Access limitations
• (14:51) Staffing barriers
• (22:43) Mobile scheduling
• (40:38) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this episode of The Oncology Insights Podcast, I speak with Ewen Ward, Brand Director at Hanson Wade Group, about the evolution and future direction of antibody drug conjugates in oncology. Ewen explores how ADC innovation is reshaping cancer treatment, from payload design to clinical impact. He also highlights the role of global scientific collaboration through the 16th World ADC London Summit. Listen now on all major platforms!

"Antibody drug conjugates combine targeted antibodies with potent anti-cancer agents, creating therapies designed to improve precision while addressing long-standing toxicity and efficacy challenges."

Meet the guest: Ewen Ward is Brand Director at the Hanson Wade Group, where he leads the development of global scientific conferences focused on antibody-drug conjugates. With a background in biochemistry, his work centers on translating scientific challenges into impactful oncology agendas.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:28) Introduction
• (04:36) ADC definition
• (05:53) Toxicity challenges
• (06:51) Payload innovation
• (09:27) Clinical impact
• (11:52) Conference scope
• (31:43) Final Questions

The Oncology Insights Podcast is trusted and supported by innovative companies like:

World ADC London 2026

Beacon - Access to Life Sciences Data - Hanson Wade

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast

In this Lung Cancer Awareness episode of The Oncology Insights Podcast, we welcome Dr. Chi-Fu Yang, thoracic surgeon at Massachusetts General Hospital and Associate Professor of Surgery at Harvard Medical School. With last month marking Lung Cancer Awareness Month, the conversation looks at where screening stands in the United States, how criteria have changed over time, and why uptake remains lower than expected. Dr. Yang also walks through effective outreach approaches, practical advocacy efforts, and new global findings that may guide the future of early detection. Listen now on all major platforms!

“The complexity of current screening criteria places a major burden on primary care teams because calculating detailed smoking exposure during short clinic visits is often unrealistic.”

Meet the guest: Dr. Chi-Fu Yang is a thoracic surgeon at Massachusetts General Hospital and an Associate Professor of Surgery at Harvard Medical School. His work spans minimally invasive thoracic surgery, clinical research, and national advocacy for equitable lung cancer screening. He leads major NIH- and AHRQ-funded studies, directs CAIIRE, and advances early detection across diverse communities.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:44) Introduction
• (04:25) Lung screening gaps
• (06:56) Systems barriers
• (10:08) Screening criteria
• (14:55) Eligibility reform
• (21:16) Community outreach
• (44:02) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast